Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy Profile

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy Profile

Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain

August 31, 2015 4:01 PM EDT

Novel mu-opioid receptor modulator TRV130 achieved primary endpoint

Superior safety and tolerability profile of TRV130 compared to morphine

Company to host conference call at 5:00 PM EDT

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced positive data from its randomized, double-blind,... More